Mirna Therapeutics (MIRN): Cutting PT After The MRX34 Program Was Terminated - Leerink

September 21, 2016 9:26 AM EDT
Get Alerts MIRN Hot Sheet
Price: $2.00 --0%

Rating Summary:
    1 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 10 | New: 3
Trade MIRN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Michael Schmidt, reiterated his Market Perform rating on shares of Mirna Therapeutics. (NASDAQ: MIRN) after the company announced termination of the ongoing Phase I trial and all planned future trials of lead product candidate MRX34 following the occurrence of additional severe adverse events in the study.

The price target drops to $1.50 from $4.00. MIRN ended 2Q16 with $73M in cash, and mgmt. guided to ~$6M near-term cash burn per quarter. This new PT reflects MIRN's estimated cash balance in 1 year.

For an analyst ratings summary and ratings history on Mirna, Inc. click here. For more ratings news on Mirna, Inc. click here.

Shares of Mirna, Inc. closed at $2.46 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment